Programs

Biomarker Data Repository

C-Path is developing a repository for data on novel translational safety biomarkers from drug development programs, with the goal of accelerating qualification of novel biomarkers as new tools for drug developers. This initial pilot focuses on kidney safety biomarkers.

Coalition Against Major Diseases

The Coalition Against Major Diseases (CAMD) is a public-private partnership aimed at creating new tools and methods that can be applied to increase the efficiency of the development process of new treatments for Alzheimer’s disease (AD) and related neurodegenerative disorders with impaired cognition and function.

Coalition For Accelerating Standards and Therapies

CFAST is an initiative formed in June 2012 to accelerate clinical research and medical product development by creating and maintaining data standards, tools and methods for conducting research in therapeutic areas that are important to public health.

Critical Path for Parkinson's

Created in partnership with Parkinson’s UK, one of the world’s largest charity funders of Parkinson’s research, the Critical Path for Parkinson’s Consortium (CPP) was launched on October 14, 2015.

Critical Path to TB Drug Regimens

The CPTR initiative is dedicated to delivering a safer, more efficacious, and faster-acting tuberculosis (TB) regimen by developing and promoting innovative regulatory science essential for supporting new combination drug development in collaboration with its partners across industry, academia, and government.

Duchenne Regulatory Science Consortium

D-RSC supports collaborative research through shared data access and development of drug development tools.

Data Collaboration Center

Developing data solutions for scientific research.

Electronic Patient-Reported Outcome Consortium

The Electronic Patient-Reported Outcome (ePRO) Consortium provides scientific leadership and best practice recommendations surrounding electronic data capture technologies and services that support the collection of patient-focused outcomes data in clinical trials.

International Neonatal Consortium

Launched on May 19, 2015, INC is C-Path’s ninth consortium – a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates.

Multiple Sclerosis Outcome Assessments Consortium

Launched in December, 2012, MSOAC is another dynamic partnership formed to promote consensus science. Created jointly with the National Multiple Sclerosis Society, MSOAC will collect, standardize, and analyze data about MS with the goal of qualifying a new measure of disability as a primary or secondary endpoint for future trials of MS therapies.

Polycystic Kidney Disease Outcomes Consortium

C-Path's Polycystic Kidney Disease (PKD) Outcomes Consortium is a collaborative partnership whose research leads to discovery of treatments for PKD.

Patient-Reported Outcome Consortium

The Patient-Reported Outcome Consortium supports patient-focused drug development by obtaining qualification of clinical outcome assessment tools that measure how patients feel and function in their everyday lives as a result of treatment.

Predictive Safety Testing Consortium

C-Path's Predictive Safety Testing Consortium (PTSC) serves as a neutral third party in the independent assessment and validation of drug safety tests.

Pediatric Trials Consortium

PTC is committed to enabling the creation of a sustainable solution that assures the timely and efficient evaluation of innovative drugs, biologics and devices for children by delivering the regulatory-quality data needed for product labeling.

Type 1 Diabetes Consortium

The T1D Consortium is working to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of therapies for the treatment, and ultimately the prevention, of type 1 diabetes.

TB-Platform for Aggregation of Clinical TB Studies

The TB-PACTS data platform is designed to catalyze and accelerate TB research by curating and standardizing Phase III tuberculosis (TB) clinical trial data and making this data publicly available to qualified researchers.

Transplant Therapeutics Consortium

Co-founded by the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS), the Transplant Therapeutics Consortium (TTC) is a collaboration between the transplant community, industry, and regulatory agencies, and is managed and supported by Critical Path Institute (C-Path).